Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.94 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.72 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377886 | 1.00 | DPP4 (0.94) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL7852579 | 1.00 | DPP4 (0.94) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL7858456 | 1.00 | DPP4 (0.94) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL8473470 | 0.92 | DPP4 (0.80) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL8474063 | 0.89 | DPP4 (0.76) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL8474414 | 0.89 | DPP4 (0.76) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14535255 | 0.88 | DPP4 (0.77) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14421644 | 0.88 | DPP4 (0.74) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL4665021 | 0.87 | DPP4 (0.72) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL8486286 | 0.85 | DPP4 (0.70) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | GLP1R, GPR119, SLC5A2 | DPP4 12/4885DPP7 26/4885DPP8 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.